LPCN
Companies
NASDAQ
Lipocine Inc.
Health Care
$3.29
-$1.59 (-32.52%)
Price Chart
Overview
About LPCN
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
Market Cap
$40.2M
Volume
349.6K
Avg. Volume
140.2K
P/E Ratio
-2.935484
Dividend Yield
0.00%
Employees
18.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.95
Moderate Correlation
Volatility
High (0.79)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, LPCN shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$40.2M
Volume349.6K
P/E Ratio-2.94
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 8, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025